Sara Chaffee
Duke University
35 Papers
691 Citations
Sara Chaffee is an academic researcher from Duke University. The author has contributed to research in topics: Chemotherapy & Leukemia. The author has an hindex of 16, co-authored 35 publications. Previous affiliations of Sara Chaffee include University Medical Center New Orleans & Miles Laboratories.
Chat about Author
Papers
High-dose chemotherapy with autologous stem-cell rescue in patients with recurrent and high-risk pediatric brain tumors.
Michael L. Graham,James E. Herndon,J. R. Casey,Sara Chaffee,G. Ciocci,Jeffrey P. Krischer,Joanne Kurtzberg,Mary J. Laughlin,Darryl C. Longee,Janice F. Olson,N Paleologus,C N Pennington,Henry S. Friedman +12 more
TL;DR: The toxicity of these regimens was tolerable and certain patients with high-risk CNS malignancies may benefit from such a treatment approach, and subsequent trials should attempt to determine which patients are most likely to benefit from high-dose chemotherapy with autologous stem-cell rescue.
166
Use of site-directed mutagenesis to enhance the epitope-shielding effect of covalent modification of proteins with polyethylene glycol.
Michael S. Hershfield,Sara Chaffee,Lillian Koro-Johnson,Ann Mary,Albert A. Smith,Steven A. Short +5 more
TL;DR: A strategy for introducing additional sites for PEG attachment by using site-directed mutagenesis to selectively replace arginine with lysine codons and tested it with purine nucleoside phosphorylase from Escherichia coli, an extremely stable but immunogenic enzyme, that could potentially be used to treat an inherited deficiency of PNP.
152
IgG antibody response to polyethylene glycol-modified adenosine deaminase in patients with adenosine deaminase deficiency.
TL;DR: PEG-modification largely prevents the development of high affinity, or high levels of clearing antibodies to bovine ADA, and that PEG-modified human ADA should be further investigated as a possible treatment for ADA deficiency.
Enzyme replacement therapy with polyethylene glycol-adenosine deaminase in adenosine deaminase deficiency: overview and case reports of three patients, including two now receiving gene therapy
TL;DR: Recovery of specific immune function during treatment with PEG-ADA is illustrated for three patients, who represent early, delayed, and late onset of immunodeficiency disease.
Phenotypic variation in the response to the human immunodeficiency virus among derivatives of the CEM T and WIL-2 B cell lines.
Sara Chaffee,J M Leeds,T J Matthews,Kent J. Weinhold,Michael A. Skinner,Dani P. Bolognesi,Michael S. Hershfield +6 more
TL;DR: A panel of related cell lines with different host-virus phenotypes could be useful for more precisely defining steps in the infectious cycle of HIV, and for identifying host cell genes and gene products that determine the outcome of HIV infection.